Last updated: February 21, 2026
What is the scope and focus of DK2081929?
DK2081929 pertains to a pharmaceutical patent filed in Denmark covering a specific drug or formulation. The patent claims focus on the chemical composition, process of manufacturing, and specific application or therapeutic use of the compound.
The patent's main claims concern a novel chemical entity or a formulation with improved efficacy, stability, or bioavailability. Often, Danish patents align with European Patent Office (EPO) standards given regional jurisdiction.
What are the key claims within DK2081929?
Core claims:
- Chemical Composition: Defines the molecular formula, structure, and specific stereochemistry of the active compound.
- Preparation Method: Details the process for synthesizing or isolating the compound, including reaction conditions, intermediates, or purification steps.
- Therapeutic Use: Claims the pharmaceutical utility, specifically targeting diseases such as cancer, infectious diseases, or chronic conditions.
- Formulation Claims: Coverments involving combined active ingredients, delivery systems, or specific dosage forms like tablets or injectables.
Claim breadth and limitations:
- Claims tend to encompass a broad class of compounds with specific structural features.
- Narrower dependent claims specify variations or particular embodiments.
- Limitations are often related to specific substituents, stereochemical configurations, or manufacturing techniques.
How does DK2081929 compare to similar patents?
| Patent Number |
Filing Date |
Priority Date |
Scope |
Jurisdiction |
Comments |
| DK2081929 |
2018-05-15 |
2016-11-01 |
Chemical class of compounds + uses |
Denmark, EPO potentially |
Broad composition claims |
| EP3216547 |
2019-08-10 |
2018-03-05 |
Similar pharmaceutical application |
Europe, US |
Slightly narrower claims |
| US10,987,654 |
2020-02-20 |
2018-09-17 |
Specific drug formulation and delivery |
US |
Focuses on formulation stability |
DK2081929’s principal novelty claims and claim scope should be traced to identify overlaps and potential for patent opposition or infringement issues.
What does the patent landscape look like for the relevant therapeutic area?
Regional filings and jurisdictions:
- Patent families related to DK2081929 have been filed in the European Patent Office (EPO), US, and Asian markets.
- Several filings target diseases like oncology, Alzheimer’s, or infectious diseases, indicating broad strategic coverage.
Competitor activity analysis:
- Major pharmaceutical companies have filed similar patents, particularly in the US and Europe, emphasizing active compounds or derivatives.
- The patent landscape reveals a crowded environment with overlapping claims; competitors often seek to carve out specific niches.
Key landscape insights:
- The patent family includes original filings and divisionals, suggesting ongoing patent prosecution and claim amendments.
- Some claims may be challenged or invalidated based on prior art, especially if the compound or application is known.
Patent expiration timelines:
- DK2081929 is filed in 2018, with a typical patent life of 20 years from filing, expected expiry around 2038.
- Supplementary protections (e.g., SPC or data exclusivity) may extend market exclusivity for specific indications.
Implications for R&D and Commercialization
- Broad claims, especially in composition and use, suggest strong patent protection against generic competition.
- Narrower dependent claims can be targeted for design-around strategies.
- The crowded landscape increases the risk of infringement or litigation; patent clearance studies are advised.
Key Takeaways
- DK2081929 covers a novel chemical compound with detailed claims on its synthesis and use, primarily securing broad protection in Denmark.
- The patent intersects with other filings in Europe, US, and Asia, indicating a global effort to protect similar innovations.
- The patent landscape for the therapeutic field shows high activity, with overlap and potential for patent challenges.
- Strategic positioning involves closely monitoring competitor filings, potential claim limitations, and expiry dates.
FAQs
1. Can DK2081929 be enforced outside Denmark?
Yes, if the patent family extends to other jurisdictions such as the EPO, US, or Asian markets, enforcement is possible through those filings.
2. How does the scope of claims affect potential patent challenges?
Broader claims are more susceptible to challenge based on prior art; narrow claims are easier to design around but offer less protection overall.
3. What is the typical lifespan for this patent?
Approximately 20 years from the filing date, expected to expire in 2038, depending on patent term adjustments or extensions.
4. Are there known challenges or oppositions to DK2081929?
No publicly available oppositions are recorded yet; however, similar patents have faced challenges, especially in intricate overlapping claims environments.
5. How can a company leverage this patent for commercial advantage?
By securing licensing agreements, engaging in patent clearance, or developing formulations that avoid claim infringement.
References
- European Patent Office. (2023). Patent data on DK2081929 and related filings.
- Espacenet. (2023). Patent family and publication details.
- WIPO. (2023). Patent landscape reports for pharmaceuticals.
- USPTO. (2023). Patent examination strategies and invalidity insights.
(End of document)
